铜和金硫代硫酸盐在活性炭上的吸附机理

研究活性炭对铜和金硫代硫酸盐的吸附机理。铜和金硫代硫酸盐在活性炭上的吸附动力学均符合准二级动力学模型。活性炭对铜硫代硫酸盐的吸附等温线符合Freundlich模型,而对金硫代硫酸盐的吸附等温线符合Langmuir模型。负载活性炭的键合特性分析表明,活性炭对铜和金的吸附机理不同。在实验条件下,活性炭对铜的吸附量达到79.04 mg/g,比金的吸附量高出约2个数量级。这意味着由于金的吸附量低以及铜和硫代硫酸盐的竞争吸附,用活性炭从硫代硫酸盐浸出液中回收金将面临很大的挑战。

Factors associated with failure of enhanced recovery after surgery program in patients undergoing pancreaticoduodenectomy

Background: The enhanced recovery after surgery (ERAS) protocol is an evidence-based perioperative care program aimed at reducing surgical stress response and accelerating recovery. However, a small propor- tion of patients fail to bene t from the ERAS program following pancreaticoduodenectomy. This study aimed to identify the risk factors associated with failure of ERAS program in pancreaticoduodenectomy. Methods: Between May 2014 and December 2017, 176 patients were managed with ERAS program fol-lowing pancreaticoduodenectomy. ERAS failure was indicated by prolonged hospital stay, unplanned read- mission or unplanned reoperation. Demographics, postoperative recovery and compliance were compared of those ERAS failure groups to the ERAS success group. Results: ERAS failure occurred in 59 patients, 33 of whom had prolonged hospital stay, 18 were readmitted to hospital within 30 days after discharge, and 8 accepted reoperation. Preoperative American Society of Anesthesiologists (ASA) score of ≥III (OR = 2.736;95% CI: 1.276 6.939;P=0.028) and albumin (ALB) level of <35g/L (OR=3.589;95% CI: 1.403 9.181;P=0.008) were independent risk factors associated with prolonged hospital stay. Elderly patients (>70 years) were on a high risk of unplanned reoperation (62.5% vs. 23.1%, P=0.026). Patients with prolonged hospital stay and unplanned reoperation had delayed intake and increased intolerance of oral foods. Prolonged stay patients got off bed later than ERAS success patients did (65h vs. 46h, P =0.012). Unplanned reoperation patients tended to experience severer pain than ERAS success patients did (3 score vs. 2 score, P =0.035). Conclusions: Patients with high ASA score, low ALB level or age >70 years were at high risk of ERAS failure in pancreaticoduodenectomy. These preoperative demographic and clinical characteristics are important determinants to obtain successful postoperative recovery in ERAS program.

Predicting surgical site infections using a novel nomogram in patients with hepatocelluar carcinoma undergoing hepatectomy

BACKGROUND Surgical site infections (SSI) remain a major cause of morbidity after hepatectomy for hepatocellular carcinoma (HCC).AIM To identify the risk factors associated with SSI,and develop a nomogram to predict SSI among patients undergoing hepatectomy.METHODS We retrospectively reviewed the data of patients diagnosed with HCC undergoing hepatectomy at two academic institutions in China,and evaluated the occurrence of SSI.Independent risk factors for SSI were identified using univariate and multivariate analyses.Based on these independent risk factors,a nomogram was established using the data of patients in the first institution,and was validated using data from an external independent cohort from the second institution.RESULTS The nomogram was established using data from 309 patients,whereas the validation cohort used data from 331 patients.The operation duration,serum albumin level,repeat hepatectomy,and ASA score were identified as independent risk factors.The concordance index (C-index) of the nomogram for SSI prediction in the training cohort was 0.86;this nomogram also performed well in the external validation cohort,with a C-index of 0.84.Accordingly,we stratified patients into three groups,with a distinct risk range based on the nomogram prediction,to guide clinical practice.CONCLUSION Our novel nomogram offers good preoperative prediction for SSIs in patients undergoing hepatectomy.

Probable sirolimus-induced rupture of arterial anastomosis after liver transplantation in a patient intolerant of tacrolimus

To the Editor:Liver transplantation remains the only cure for end-stage liver disease.Tacrolimus is widely used as a first-line immunosuppressive drug to prevent organ rejection after liver transplantation[1–3].However,tacrolimus has a narrow therapeutic index and wide inter-individual variability in pharmacokinetics,which can result in underimmunosuppression or toxicity.Orally administered tacrolimus is rapidly absorbed from the distal gastrointestinal tract and extensively metabolized in the liver and intestinal walls by cytochrome P450(CYP)3A4 and 3A5[2,4,5].

Combined targeted therapy and immunotherapy for cancer treatment

Although targeted therapies and immunotherapies have been effective againstseveral malignancies, the respective monotherapies are limited by low and/orshort-term responses. Specific inhibitors of oncogenic signaling pathways andtumor-associated angiogenesis can activate the anti-tumor immune responses byincreasing tumor antigen presentation or intratumor T cell infiltration. Additionalinsights into the effects and mechanisms of targeted therapies on the induction ofanti-tumor immunity will facilitate development of rational and effective combinationstrategies that synergize rapid tumor regression and durable response. Inthis review, we have summarized the recent combinations of targeted therapiesand immunotherapies, along with the associated clinical challenges.

Commentary on“The tumour microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma”

We read with great interest the article by Heinrich et al.that investigated the roles of innate lymphoid cells(ILCs)and their regulatory cytokines in the hepatocellular carcinoma(HCC)tumor microenvironment(TME)(1).The authors demonstrated a relationship between the expression of cytokines in the HCC TME and patient prognosis.The total cells and cytokines from tumor(T),non-tumor(NT),and margin(M)tissues were extracted from HCC patients.Using bulk tissue RNA sequencing and unbiased clustering,gradual changes in mRNA expression between NT,M,and T tissues were confirmed.